Colorectal Cancer Viva

Long Case Viva Defence

Opening statement

"This patient presents with a problem best framed as Colorectal Cancer. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]

Examiner questions

Q1: "What makes this urgent?" [1]

"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]

Q2: "What is your first investigation package?" [2]

"I order tests that change management now, not a scattergun panel." [1] [2]

Q3: "Walk me through treatment." [1]

"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]

Q4: "What is the classic trap?" [2]

"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]

Short case

Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]

References

[1]Marmo R, Venezia L, Galeazzi F, Cannizzaro R, et al. Programme-level determinants of participation in colorectal cancer screening in Italy: a national cross-sectional study BMC Public Health, 2026.PMID 42469726
[2]Laforce-van Lierop LMA, Dang R, Narula N, Ingram RJM, et al. The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease BMC Gastroenterol, 2026.PMID 42469662
[3]Zhen J, Dong M, Li Y, Cao B, et al. Human salivary microbiome as a potential non-invasive biomarker for early-onset colorectal cancer screening: a prospective study BMC Microbiol, 2026.PMID 42469627
[4]Lu TF, Shih YH, Chen YF, Fan CT, et al. Association of Hormone Therapy with Long-Term Outcomes After Chemoradiation for Locally Advanced Cervical Cancer Am J Obstet Gynecol, 2026.PMID 42468866
[5]Raja NP, Kandagari N Neoadjuvant Imatinib Therapy in Rectal Gastrointestinal Stromal Tumors: A Comprehensive Narrative Review of Tumor Downsizing, Sphincter Preservation, Transanal Surgical Platforms, Functional Outcomes, and Survival J Gastrointest Cancer, 2026.PMID 42467291
[6]Buali HF, Al Shaibani A, Farouqi US, Abushloa T, et al. Prostate Cancer Screening: Current Controversies and Future Directions Cureus, 2026.PMID 42465149
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

Long Case Viva Defence

Opening statement

Examiner questions

Q1: "What makes this urgent?" [1]

"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]

Q2: "What is your first investigation package?" [2]

"I order tests that change management now, not a scattergun panel." [1] [2]

Q3: "Walk me through treatment." [1]

"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]

Q4: "What is the classic trap?" [2]

"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]

Short case

Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]

References

[1]Marmo R, Venezia L, Galeazzi F, Cannizzaro R, et al. Programme-level determinants of participation in colorectal cancer screening in Italy: a national cross-sectional study BMC Public Health, 2026.PMID 42469726
[2]Laforce-van Lierop LMA, Dang R, Narula N, Ingram RJM, et al. The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease BMC Gastroenterol, 2026.PMID 42469662
[3]Zhen J, Dong M, Li Y, Cao B, et al. Human salivary microbiome as a potential non-invasive biomarker for early-onset colorectal cancer screening: a prospective study BMC Microbiol, 2026.PMID 42469627
[4]Lu TF, Shih YH, Chen YF, Fan CT, et al. Association of Hormone Therapy with Long-Term Outcomes After Chemoradiation for Locally Advanced Cervical Cancer Am J Obstet Gynecol, 2026.PMID 42468866
[5]Raja NP, Kandagari N Neoadjuvant Imatinib Therapy in Rectal Gastrointestinal Stromal Tumors: A Comprehensive Narrative Review of Tumor Downsizing, Sphincter Preservation, Transanal Surgical Platforms, Functional Outcomes, and Survival J Gastrointest Cancer, 2026.PMID 42467291
[6]Buali HF, Al Shaibani A, Farouqi US, Abushloa T, et al. Prostate Cancer Screening: Current Controversies and Future Directions Cureus, 2026.PMID 42465149
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

Colorectal Cancer — Viva Defence

Colorectal Cancer Viva

Long Case Viva Defence

Opening statement

Examiner questions

Short case

References

Colorectal Cancer — Viva Defence

Colorectal Cancer Viva

Long Case Viva Defence

Opening statement

Examiner questions

Short case

References